TMCnet - World's Largest Communications and Technology Community



Global Hereditary Angioedema Market 2017-2025 - Expected to Grow at a CAGR of 8.19% -
[February 13, 2018]

Global Hereditary Angioedema Market 2017-2025 - Expected to Grow at a CAGR of 8.19% -

The "Global Hereditary Angioedema Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to's offering.

The global hereditary angioedema market was valued at US$ 1,750.2 Million in 2016, and is expected to reach US$ 3,689.4 Million by 2025 expanding at a CAGR of 8.19% from 2017 to 2025.

In 2016, C1 esterase inhibitors segment dominated the market due to the recent approval of novel drugs: Berinert and Haegarda. Additionally, technological advancement in drug delivery (for e.g. Haegarda is the only medication available as a subcutaneous treatment option).

Kallikrein inhibitors is expected to be the fastest growing segment throughout the forecast period 2017-2025, majorly due to increasing incidences in patients with severe angioedema anaphylactic shock and promising prduct pipeline, touted to offer better results than the existing treatment options.

The drug in Phase III DX 2930 has received breakthrough therapy designation and orphan drug designation by the USFDA. Phase II drug BCX-7353 is an oral preparation to counteract the severe swelling attacks in the intestinal and airway tract.

Asia Pacific will be the fastest growing market throughout the forecast period 2017-2025, majorly due to factors such as increasing frequency of symptoms in patients suffering with hereditary angioedema requiring immediate medical intervention, increasing disposable incomes in these regions and supportive regulatory environment for hereditary angioedema drugs.

Key Market Movements:

  • Increasing incidences of underlying symptoms reflecting association with hereditary angioedema
  • Supportive regulatory environment for hereditary angioedema drugs
  • Affordable reimbursement scenario for the treatment of rare genetic diseases in the developed countries

Company Profiles

  • BioCryst Pharmaceuticals, Inc.
  • Cipla, Inc.
  • CSL Behring Ltd.
  • iBio, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Pharming Group NV
  • Sanofi N.V.
  • Shire plc.
  • Teva Pharmaceutical Industries, Ltd.

For more information about this report visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy